Clearmind Briefs FDA on Psychedelic Therapy and Patient Access
VANCOUVER, Canada — September 17, 2026 Clearmind Medicine announced that its Chief of Global Impact, Mary-Elizabeth Gifford, testified at...
Addiction Treatment
Advertisement
Clearmind Medicine Advances CMND-100 Into AUD Clinical Trial
VANCOUVER, Canada — September 11, 2026 Clearmind Medicine Inc. announced that the first patients with Alcohol Use Disorder (AUD)...
Persica Strengthens PP353 Case in Vertebrogenic Back Pain
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
Clearmind Advances CMND-100 Into Phase IIa Trial for Alcohol Use Disorder
Vancouver, Canada — September 1, 2026 Clearmind Medicine Inc. announced the initiation of Phase IIa development for CMND-100, its...
Kedrion Extends U.S. Agreement to Support GAMMAKED Access
FORT LEE, N.J., August 18, 2026 Kedrion Biopharma announced an extension of its U.S. agreement with Grifols to continue...
Advertisements
Amygdala Advances ANS-858 After FDA IND Clearance
PALO ALTO, Calif., August 18, 2026 Amygdala Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Clear Scientific Gains FDA Fast Track for CS-1103
CAMBRIDGE, Mass., May 6, 2026 Clear Scientific Inc., a clinical-stage biopharmaceutical company developing innovative therapies for acute drug intoxication,...
Advertisement
